CYP4F2 encodes a cytochrome P450 enzyme¹¹ cytochrome P450 enzyme
The CYP4F2 enzyme is the primary hepatic vitamin K1 oxidase that metabolizes vitamin K1 to hydroxyvitamin K1, effectively removing it from the vitamin K cycle. This serves as a counterbalance to VKORC1 (vitamin K epoxide reductase), preventing excessive accumulation of vitamin K. The V433M variant, also known as CYP4F2*3, is a common missense mutation that significantly impacts warfarin dosing requirements²² warfarin dosing requirements
Warfarin is an anticoagulant that works by inhibiting VKORC1, thereby limiting vitamin K availability for clotting factor activation.

The Mechanism

The rs2108622 variant causes a valine-to-methionine substitution at position 433 in the CYP4F2 protein. Research using human liver microsomes³³ human liver microsomes
Tissue samples analyzed from liver banks genotyped for this variant demonstrates that individuals carrying the T allele (433Met) have both reduced CYP4F2 protein concentrations and decreased vitamin K1 oxidation activity. The T allele is associated with approximately 40-45% reduction in enzyme activity compared to the wild-type. Because less vitamin K is being metabolized and removed, hepatic vitamin K1 levels rise, providing more substrate for VKORC1 to convert into the active form needed for clotting factor synthesis. This elevated vitamin K counteracts warfarin's anticoagulant effect, necessitating higher warfarin doses to achieve the same therapeutic response.

The Evidence

The association between CYP4F2*3 and warfarin dosing was first identified in 2008⁴⁴ first identified in 2008
Caldwell et al. CYP4F2 genetic variant alters required warfarin dose. Blood, 2008 through a genome-wide association study that screened over 1,200 SNPs in a cohort of warfarin patients. The discovery study found that TT homozygotes required approximately 1 mg/day more warfarin than CC homozygotes across three independent cohorts representing diverse US geographic regions.

This finding has been extensively replicated worldwide⁵⁵ extensively replicated worldwide
Liang et al. Influence of CYP4F2 genotype on warfarin dose requirement: a systematic review and meta-analysis. Thrombosis Research, 2012. A 2012 meta-analysis of 30 studies involving 9,470 participants confirmed that T-allele carriers require an 8.3% higher mean daily coumarin dose than CC homozygotes (95% CI: 5.6-11.1%, P < 0.0001). The effect is consistent across European and Asian populations but appears less pronounced in individuals of African ancestry, where the T allele is also much rarer.

The Clinical Pharmacogenetics Implementation Consortium (CPIC)⁶⁶ Clinical Pharmacogenetics Implementation Consortium (CPIC)
Johnson et al. CPIC Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clinical Pharmacology & Therapeutics, 2017 incorporated CYP4F2*3 into their 2017 warfarin dosing guideline update. While the effect size is smaller than that of CYP2C9 and VKORC1 variants (which collectively explain ~40% of dose variability), CYP4F2*3 contributes an additional 1-4% to the explained variance and improves the accuracy of pharmacogenetic dosing algorithms.

Practical Implications

If you are prescribed warfarin and carry one or two copies of the T allele, you will likely need a higher maintenance dose to reach your target INR (International Normalized Ratio, typically 2-3 for most indications). CPIC recommends an optional 5-10% dose increase for non-African American individuals with at least one T allele when using a pharmacogenetic algorithm that already accounts for CYP2C9 and VKORC1 genotypes. This translates to approximately 0.5-1 mg/day additional warfarin.

The effect appears most clinically relevant in patients who also carry VKORC1 variants associated with low warfarin requirements. In these individuals, CYP4F2*3 can explain a significant portion of the remaining dose variability. The interaction makes sense mechanistically: VKORC1 variants that increase warfarin sensitivity reduce the amount of active vitamin K, while CYP4F2*3 increases available vitamin K — the two variants work in opposite directions.

It's important to note that CYP4F2 testing is considered optional rather than essential in clinical warfarin management. The major determinants remain CYP2C9 (which metabolizes warfarin itself) and VKORC1 (warfarin's direct target). However, incorporating CYP4F2*3 into dosing algorithms does incrementally improve prediction accuracy and may be particularly valuable for patients who are difficult to stabilize or who fall outside the predicted dose range from CYP2C9/VKORC1 alone.

Interactions

CYP4F2*3 is one of four genetic variants incorporated into modern pharmacogenetic warfarin dosing algorithms, alongside VKORC1 rs9923231, CYP2C9*2 (rs1799853), and CYP2C9*3 (rs1057910). For individuals of African ancestry, the CYP2C cluster variant rs12777823 is more clinically relevant than CYP4F2*3.

The combined effect of these variants is complex but predictable. A person with VKORC1 AA genotype (high warfarin sensitivity) plus CYP2C9*1/*1 (normal metabolism) plus CYP4F2 TT (reduced vitamin K metabolism) represents competing influences: the VKORC1 variant lowers dose requirements substantially, while CYP4F2 TT modestly increases them. The net effect is still a lower-than-average dose, but not as low as VKORC1 AA alone would predict. Modern dosing algorithms such as those validated by the International Warfarin Pharmacogenetics Consortium⁷⁷ such as those validated by the International Warfarin Pharmacogenetics Consortium
Available at www.warfarindosing.org incorporate all these variants simultaneously to generate personalized dose predictions.

Gene-gene interactions worth noting for compound implications include CYP4F2 TT + VKORC1 low-sensitivity genotypes (requiring careful upward dose titration) and CYP4F2 TT + CYP2C9 poor metabolizer status (where warfarin clearance is slow but more drug is needed to overcome elevated vitamin K). However, these interactions are generally handled by existing pharmacogenetic algorithms rather than requiring separate clinical decision-making.

The PER3 gene encodes Period Circadian Regulator 3¹¹ Period Circadian Regulator 3
One of three Period proteins (PER1, PER2, PER3) that form the negative arm of the mammalian circadian clock feedback loop, a protein at the heart of the molecular clock that governs your ~24-hour sleep-wake cycle. Every cell in your body runs a version of this clock, and PER3 helps set its tempo. The rs228697 variant swaps a proline for an alanine at position 864, subtly changing how the clock protein behaves — and, with it, whether you lean toward being a morning lark or a night owl.

PER3 is best known for its VNTR polymorphism²² VNTR polymorphism
A variable number tandem repeat (4 or 5 copies of a 54-bp repeat) in exon 18 that strongly influences sleep timing and homeostatic sleep drive, but is not on SNP genotyping chips (4-repeat vs 5-repeat), which strongly predicts sleep timing and sleep need but cannot be genotyped on standard SNP chips. The Pro864Ala missense variant (rs228697) is the best SNP-chip proxy for PER3 circadian effects and has its own independent functional consequences.

The Mechanism

The circadian clock runs on a transcription-translation feedback loop³³ transcription-translation feedback loop
CLOCK and BMAL1 proteins activate transcription of PER and CRY genes; the PER/CRY protein complex then feeds back to repress CLOCK-BMAL1, creating a ~24-hour oscillation. CLOCK and BMAL1 proteins bind to E-box elements⁴⁴ E-box elements
Short DNA sequences (CACGTG) in gene promoters that CLOCK-BMAL1 heterodimers recognize to activate transcription of clock-controlled genes to activate PER and CRY genes. The resulting PER and CRY proteins accumulate, form complexes, enter the nucleus, and repress their own transcription — completing one cycle roughly every 24 hours.

The Pro864Ala substitution sits in a region containing two potential SH3-binding motifs⁵⁵ SH3-binding motifs
Src Homology 3 domains mediate protein-protein interactions; the proline-to-alanine change disrupts these binding sites, altering how PER3 interacts with partner proteins. Replacing proline (a rigid amino acid that enforces tight bends in protein structure) with alanine (a flexible, small amino acid) alters the local protein conformation. Functional experiments⁶⁶ Functional experiments
Lavebratt C et al. Molecular analyses of circadian gene variants. Transl Psychiatry, 2016 showed that the variant (G allele) protein is more stable than the wild-type — it degrades more slowly, accumulates to higher levels, and recruits more PER2 into the transcription repression complex. The result is a stronger repressor of CLOCK-BMAL1-driven transcription.

When the variant hPER3 was expressed in mammalian fibroblasts, it caused a significant, dose-dependent lengthening of the circadian period. A computational model⁷⁷ computational model
Liberman AR et al. Circadian clock model supports molecular link between PER3 and human anxiety. Sci Rep, 2017 estimated this lengthening at 2-6% — enough to shift a 24-hour period toward roughly 25 hours. People whose internal clock runs long tend to drift toward later sleep and wake times — the hallmark of evening chronotype.

The Evidence

The initial genetic association⁸⁸ initial genetic association
Hida A et al. Screening of clock gene polymorphisms demonstrates association of a PER3 polymorphism with morningness-eveningness preference and circadian rhythm sleep disorder. Sci Rep, 2014 came from a Japanese study of 925 controls, 182 delayed sleep phase patients, and 67 free-running type patients. The G allele was significantly associated with eveningness preference (sex-adjusted OR 2.48, 95% CI 1.34-4.60, corrected P = 0.012). More strikingly, G allele frequency was doubled in free-running type patients — people whose internal clock fails to entrain to the 24-hour day (age- and sex-adjusted OR 2.02, 95% CI 1.16-3.52, P = 0.017).

An Italian replication study⁹⁹ Italian replication study
Lazar AS et al. Diurnal preference, mood and the response to morning light in relation to polymorphisms in the human clock gene PER3. Sci Rep, 2017 of 786 Caucasian subjects confirmed the chronotype association (OR 2.10, 95% CI 1.21-3.65, P = 0.008) and found that G carriers showed lower mood scores in the late afternoon and early evening — the time when a longer-period clock would be most misaligned with the external day.

Beyond chronotype, a case-control study¹⁰¹⁰ case-control study
Lavebratt C et al. Molecular analyses of circadian gene variants reveal sex-dependent links between depression and clocks. Transl Psychiatry, 2016 of 592 major depressive disorder (MDD) cases and 776 controls found the G allele associated with MDD risk (OR 1.39, allelic P = 0.007), with a stronger effect in women (allelic P = 0.041). Separately, anxiety levels¹¹¹¹ anxiety levels
Liberman AR et al. Sci Rep, 2017 were significantly higher in G allele carriers (F(2,305) = 3.195, P = 0.042), consistent with the broader finding that circadian misalignment elevates anxiety and depression risk.

Practical Implications

This variant does not cause disease. It shifts your circadian tendency. If you carry the G allele and find yourself naturally gravitating toward later bedtimes, the biology supports what you already feel. The key is to work with your chronotype rather than fight it:

Morning light exposure is the most powerful tool for advancing a late-running clock. Even 20-30 minutes of outdoor light before 10 AM can shift your circadian phase earlier. Conversely, avoiding bright light (especially blue-enriched screens) in the 2-3 hours before desired bedtime prevents the clock from being pushed even later.

Meal timing also entrains peripheral clocks. Eating your last substantial meal at least 3 hours before sleep, and anchoring breakfast to a consistent time, provides a secondary timing cue that reinforces the light signal.

For the mood dimension, the association between this variant and depression/anxiety appears to operate through circadian misalignment rather than a direct effect on mood neurocircuitry. Maintaining regular sleep-wake timing — even on weekends — reduces social jetlag¹²¹² social jetlag
The discrepancy between your biological clock and your social schedule, measured as the difference between midpoint of sleep on work days vs free days and may mitigate the mood risk.

Interactions

PER3 Pro864Ala interacts with the PER3 VNTR (4-repeat vs 5-repeat). The G allele combined with the PER3-4 repeat haplotype shows a stronger association with morningness than either variant alone (OR 2.19 for the haplotype vs OR 2.10 for the SNP alone). However, the VNTR is not genotyped on standard SNP chips, so this interaction cannot be assessed from 23andMe data.

PER3 is part of a broader circadian gene network including CLOCK, BMAL1 (ARNTL), PER1, PER2, CRY1, and CRY2. Variants in these genes may compound or buffer PER3 effects on chronotype, but specific SNP-SNP interactions with rs228697 have not been well characterized in the published literature.

Where you store fat matters as much as how much fat you carry. Two people with identical BMIs can have very different metabolic and health profiles depending on whether fat accumulates centrally (around the abdomen) or peripherally (in the hips, buttocks, and legs). The LYPLAL1 locus on chromosome 1q41 is one of the earliest and most replicated genetic signals for waist-hip ratio adjusted for BMI¹¹ waist-hip ratio adjusted for BMI
WHR-adjBMI is a phenotype that captures fat distribution independently of total adiposity — it reflects where fat is located, not how much there is, and its effects are dramatically stronger in women than in men.

rs2605100 sits within an intronic region of the LYPLAL1 antisense RNA 1 gene (LYPLAL1-AS1), approximately 259 kb from the LYPLAL1 protein-coding gene itself. LYPLAL1 (Lysophospholipase-Like 1) encodes a serine hydrolase with unclear endogenous substrate²² serine hydrolase with unclear endogenous substrate
Crystal structure shows LYPLAL1 is structurally similar to acyl-protein thioesterases but with a closed hydrophobic tunnel preferring short acyl chains; it has been proposed to act as a triglyceride lipase in adipose tissue and to regulate protein depalmitoylation. Despite its name, the protein is not a classical lysophospholipase. Its precise physiological substrate and pathway remain under active investigation.

The Mechanism

The G allele at rs2605100 is the major allele (frequency ~71% in Europeans, up to ~89% in Africans) and is the variant associated with higher WHR — meaning more centrally distributed fat — in women. The A allele is the protective (favorable) form linked to a more gynoid (hip-and-thigh-predominant) fat distribution pattern. The variant likely acts as a regulatory signal rather than directly altering the LYPLAL1 protein sequence, possibly influencing the expression of LYPLAL1 or its antisense RNA in adipose tissue.

Mouse knockout studies³³ Mouse knockout studies
CRISPR-Cas9 whole-body Lyplal1 KO on high-fat/high-sucrose diet; n=20 per sex per diet demonstrate a sex-specific role: female (but not male) Lyplal1 KO mice on a high-fat, high-sucrose diet weighed approximately 5 g less than wildtype controls, had reduced total body fat percentage, and showed smaller white adipose tissue depots across inguinal, gonadal, and perirenal sites. This mirrors the human GWAS pattern where LYPLAL1 variants affect fat distribution exclusively or predominantly in women. One proposed mechanism is that LYPLAL1 functions as an acyl thioesterase involved in protein palmitoylation⁴⁴ protein palmitoylation
Palmitoylation is the reversible attachment of palmitate to cysteine residues, which regulates membrane targeting and activity of proteins including estrogen receptors and metabolic signaling intermediates, potentially influencing estrogen receptor localization and thus coupling the gene's function to sex hormone signaling.

The Evidence

The original discovery came from a meta-analysis of 38,580 individuals⁵⁵ meta-analysis of 38,580 individuals
Lindgren et al. 2009, PLoS Genetics; 32 GWAS cohorts in stage 1, followed by replication in 70,689 subjects that identified rs2605100 as the sentinel variant at the LYPLAL1 locus. The association with WHR reached genome-wide significance in women (p = 1.3×10⁻⁸) but was completely absent in men (p = 0.50). The absolute effect — 0.0014 units of WHR per G allele — is modest, explaining approximately 0.02% of WHR variance in women. This is typical for GWAS hits: individually small effects that are biologically real and replicated.

A subsequent GIANT consortium analysis⁶⁶ subsequent GIANT consortium analysis
Heid et al. 2010, Nature Genetics; n=77,167 discovery, n=113,636 replication; 32 genome-wide association studies confirmed the LYPLAL1 signal alongside 13 newly discovered loci. Seven of the 14 confirmed WHR loci showed marked sex dimorphism, all with stronger effects in women — a pattern consistent with the well-established sex differences in adipose tissue distribution driven by estrogen signaling.

Metabolic consequences of the G allele extend beyond fat location. In a Danish population study⁷⁷ Danish population study
Dalgaard et al. 2011, PLoS ONE; Inter99 cohort, n=6,038 adults, each additional G allele was associated with 3% higher fasting triglycerides (p = 0.003), 3% higher fasting insulin (p = 0.003), and 4% higher HOMA-IR (p = 0.001). Notably, the triglyceride effect was male-restricted (6% per G allele in men, p = 2.4×10⁻⁴; interaction p = 0.02), suggesting different metabolic routes through which the variant affects men vs. women.

Evidence from bariatric surgery outcomes⁸⁸ bariatric surgery outcomes
Lund et al. 2016, n=251 RYGB patients (186 women); rs4846567, which is in high LD with rs2605100 shows that individuals homozygous for the favorable T allele of the correlated SNP rs4846567 lost 7% more excess body weight after gastric bypass surgery and reported 74% lower hunger scores and 53% lower disinhibition scores on validated eating behavior questionnaires compared to G-allele carriers.

Overall, evidence for rs2605100 is strong: multiple large, independent GWAS in European and Asian populations, consistent replication, plausible biological mechanism supported by animal models, and metabolic downstream effects that extend beyond the index phenotype.

Practical Actions

For carriers of one or two copies of the G allele — particularly women — the key insight is a genetic tendency toward central fat redistribution. This does not override lifestyle factors but does establish a meaningful background predisposition. Two areas are specifically supported by the biological evidence:

First, triglyceride management is directly implicated. The G allele is associated with elevated fasting triglycerides regardless of fat distribution. Dietary approaches that specifically lower triglycerides — not generic "healthy eating" — are warranted: reducing refined carbohydrate and added sugar intake, increasing omega-3 fatty acids (EPA/DHA from marine sources), and limiting alcohol.

Second, body composition monitoring matters more than scale weight. Since the LYPLAL1 locus affects fat distribution rather than total fat mass, standard BMI tracking misses the relevant phenotype. Waist circumference and waist-hip ratio track the fat depot that this variant influences most directly.

Interactions

The LYPLAL1 locus signal is most commonly indexed by rs4846567, which is in high linkage disequilibrium⁹⁹ linkage disequilibrium
LD means the two variants are almost always co-inherited; knowing your rs2605100 genotype reliably predicts your rs4846567 genotype with rs2605100. For practical interpretation, the two variants can be treated as equivalent.

The LYPLAL1 fat distribution signal operates independently of FTO/MC4R total adiposity signals — having a high-risk FTO genotype (rs9939609 AA) drives increased overall fat mass, while LYPLAL1 determines where that fat is preferentially stored. These can compound: an individual with high-risk genotypes at both loci may gain more total fat and distribute it more centrally.

Supervisor note — candidate compound action: individuals carrying the G allele at rs2605100 (LYPLAL1, central redistribution) AND the AA genotype at rs9939609 (FTO, higher total fat mass) represent the highest-risk combination for central obesity among these two loci. A combined recommendation addressing both elevated total fat accumulation and its central distribution — specifically targeting fasting triglycerides and waist circumference rather than weight alone — would be appropriate and supported by additive effects documented in stratified GWAS analyses.

FADS2¹¹ FADS2
Fatty acid desaturase 2, encoding the delta-6 desaturase (D6D) enzyme — the first and rate-limiting step in converting the plant-based omega-3 alpha-linolenic acid (ALA) into EPA and ultimately DHA is one of the most consequential enzymes in human lipid metabolism. It processes both the omega-3 pathway (ALA → stearidonic acid → EPA) and the omega-6 pathway (linoleic acid → gamma-linolenic acid → DGLA → arachidonic acid). Without adequate FADS2 activity, the plant-based omega-3 fats in flaxseed, walnuts, and chia seeds cannot be converted into the long-chain forms that the brain, cardiovascular system, and immune cells actually use.

rs2727271 is an intronic variant within FADS2 on chromosome 11q12-13 that tags a haplotype block associated with altered FADS2 expression. The T allele appears in about 14% of Europeans but in 41% of East Asians, pointing to population-specific evolutionary pressures on fatty acid conversion capacity — likely tied to differences in dietary omega-3 sources across ancestral populations.

The Mechanism

rs2727271 sits deep within an intron of FADS2 (position c.142-1892 relative to the coding sequence), with no direct protein change. Its functional effect is presumed to be cis-regulatory — altering FADS2 mRNA transcription efficiency²² cis-regulatory — altering FADS2 mRNA transcription efficiency
Analogous to the promoter-methylation mechanism of rs174537 in FADS1, where intronic/regulatory variants in the same FADS cluster modulate expression via allele-specific DNA methylation at enhancer sites between FADS1 and FADS2. The T allele is associated with reduced enzyme activity, which produces a predictable biochemical cascade: ALA and linoleic acid accumulate because the first desaturation step is slowed, while downstream long-chain products (EPA, arachidonic acid) are produced at lower rates.

A genome-wide association study identified rs2727271-A (the major allele) as associated with decreased circulating cis/trans-18:2 fatty acid levels (p=7×10⁻⁹), consistent with A-allele carriers more efficiently converting 18:2 precursors through the desaturation pathway. By contrast, T-allele carriers accumulate more precursor fatty acids — a biochemical signature of reduced D6D throughput.

The Evidence

The strongest evidence for the FADS2 locus comes from large genome-wide association studies of circulating polyunsaturated fatty acids. A landmark 2009 GWAS in 1,075 InCHIANTI participants³³ landmark 2009 GWAS in 1,075 InCHIANTI participants
Tanaka et al., PLoS Genetics — the FADS1/2/3 cluster on chromosome 11 emerged as the dominant genetic determinant of plasma PUFA levels, with rs174537 alone explaining 18.6% of additive variance in arachidonic acid (p=5.95×10⁻⁴⁶) and associating strongly with EPA (p=1.07×10⁻¹⁴) established that natural variation at this locus has an unusually large effect on fatty acid status — larger than most single SNPs in metabolic genetics.

Subsequent studies refined the picture for FADS2 specifically. Zec et al. 2020 in Nutrition Research⁴⁴ Zec et al. 2020 in Nutrition Research
Cross-sectional study of 286 Serbian adults; FADS2 rs174576 minor allele carriers showed plasma AA β=−1.14 (95% CI: −2.25 to −0.43) and reduced estimated desaturase-5 activity after multivariate adjustment confirmed that FADS2 minor alleles consistently associate with lower arachidonic acid. Schuchardt et al. 2016⁵⁵ Schuchardt et al. 2016
111 MCI patients; FADS2 minor allele carriers at rs3834458, rs1535, rs174575, and rs174576 showed higher precursor PUFA levels and lower AA in erythrocyte membranes demonstrated that the effect on circulating PUFA composition is detectable in red blood cell membranes — the most clinically relevant tissue compartment for omega-3 status assessment.

Isotope tracer work directly quantifying in-vivo ALA conversion found that FADS minor allele homozygotes had lower plasma EPA and lower [13C]EPA enrichment at 24 and 48 hours after ALA tracer dosing⁶⁶ FADS minor allele homozygotes had lower plasma EPA and lower [13C]EPA enrichment at 24 and 48 hours after ALA tracer dosing
Gillingham et al. 2013, Am J Clin Nutr, n=103; four FADS SNPs studied across all dietary conditions, providing direct mechanistic confirmation that reduced FADS activity translates into measurably less ALA-to-EPA conversion.

The East Asian frequency of the T allele (41%) versus African populations (3%) is striking. This stratification suggests that the T allele may have been neutral or mildly adaptive in populations historically relying on preformed dietary EPA and DHA from fish, while being selected against in populations that depended more on plant-based omega-3 conversion.

Practical Actions

For T-allele carriers, the core problem is that plant-based omega-3 sources (flaxseed, chia, walnuts, hemp) are unreliable. These foods supply ALA, which requires functional FADS2 to produce EPA and DHA. The T allele slows this conversion at the first and rate-limiting step, meaning even high ALA intakes may not translate to adequate EPA and DHA status.

The practical solution is to bypass the impaired conversion step by providing preformed EPA and DHA directly — from fatty fish, concentrated fish oil, or algae-based EPA/DHA supplements. AT heterozygotes benefit from 1–2 g EPA+DHA daily; TT homozygotes require 2–4 g daily to compensate for substantially reduced D6D throughput.

Omega-3 index testing (erythrocyte EPA+DHA as a percentage of total fatty acids) provides the most direct readout of whether supplementation is working. A value below 4% indicates clinically significant deficiency requiring dose adjustment.

Interactions

rs2727271 is in linkage disequilibrium with other FADS2 cluster variants, including rs3834458, rs174575, rs174576, and rs1535. Carrying multiple minor alleles across the FADS cluster (both FADS1 rs174537 T allele and FADS2 rs2727271 T allele) would compound the conversion deficit, since FADS1 (delta-5 desaturase) acts downstream of FADS2 in the same pathway. Combined FADS1+FADS2 minor allele carriers face a double bottleneck in long-chain PUFA synthesis.

FADS2 activity is also substrate-competitive: when dietary saturated fat (palmitic acid, 16:0) is high, FADS2 preferentially processes the saturated substrate rather than ALA or linoleic acid, further reducing long-chain PUFA synthesis in T-allele carriers who have less enzyme capacity to begin with.

A single stretch of chromosome 9 — the 9p21.3 locus — is the most consistently replicated region in genome-wide association studies for age-related disease. Coronary artery disease, type 2 diabetes, glioma, melanoma, and now physical aging have all been linked to variation here. At the heart of the locus sits ANRIL (antisense non-coding RNA in the INK4 locus)¹¹ ANRIL (antisense non-coding RNA in the INK4 locus)
Also designated CDKN2BAS or CDKN2B-AS1 — a long non-coding RNA transcribed antisense to the CDKN2A/CDKN2B tumor suppressor genes, a molecular rheostat for cellular senescence.

rs2811712 is a tag SNP within ANRIL that was identified in a landmark study as associated with physical function in older people²² associated with physical function in older people
Melzer D et al. A common variant of the p16INK4a genetic region is associated with physical function in older people. Mech Ageing Dev. 2007. The G allele — carried by roughly one in five people of European ancestry — is associated with substantially better preserved physical function in old age, while the common A allele is the risk-conferring genotype.

The Mechanism

The 9p21.3 locus contains three protein-coding genes — CDKN2A (encoding p16INK4a and p14ARF), CDKN2B (encoding p15INK4b), and MTAP — all flanked and overlapped by ANRIL. p16INK4a and p15INK4b are cyclin-dependent kinase inhibitors³³ cyclin-dependent kinase inhibitors
CDK inhibitors block CDK4/6, preventing phosphorylation of Rb and halting cell-cycle progression from G1 to S phase — the canonical senescence checkpoint that drive cellular senescence: as cells age and accumulate damage, p16 levels rise, arresting the cell cycle and converting cells into senescent "zombie" cells⁴⁴ senescent "zombie" cells
Senescent cells stop dividing but remain metabolically active, secreting pro-inflammatory cytokines (the SASP — senescence-associated secretory phenotype) that damage neighboring tissue that fuel the chronic inflammation underlying age-related functional decline.

ANRIL regulates CDKN2A/CDKN2B expression in cis through Polycomb group protein recruitment, particularly the PRC2 complex, which methylates histone H3K27 to silence the INK4 locus. In proliferating cells, ANRIL keeps senescence genes suppressed; as ANRIL expression shifts with aging or genetic variation, the balance tips toward elevated p16 and p15, accelerating the senescent phenotype. rs2811712 is an eQTL for CDKN2B expression: studies show that variation here correlates with altered ANRIL isoform abundance and downstream CDKN2B levels, providing a molecular pathway from genotype to functional aging phenotype.

The Evidence

The primary association was established by Melzer et al. (2007)⁵⁵ Melzer et al. (2007)
A common variant of the p16INK4a genetic region is associated with physical function in older people. Mechanisms of Ageing and Development. across three independent European cohorts totaling 3,372 elderly individuals (EPIC-Norfolk sets 1 and 2 plus InCHIANTI). Severely limited physical function — defined by performance-based tests of walking speed, chair stand, and balance — was present in 15.0% of AA homozygotes versus 7.0% of GG homozygotes, nearly half the rate. The per-A-allele odds ratio was 1.48 (95% CI 1.17–1.88, p = 0.001), adjusted for age, sex, and study. The association held across all three cohorts tested independently, including a trend in the Iowa-EPESE cohort (n=419, p=0.079 one-sided), making this one of the first robust genetic associations for functional aging specifically.

A Han Chinese case-control study Wu et al. (2012)⁶⁶ Wu et al. (2012)
Heterozygote genotypes at rs2222823 and rs2811712 SNP loci are associated with cerebral small vessel disease in Han Chinese population found the heterozygote genotype at rs2811712 was associated with OR 1.75 (CI 1.13–2.71, p=0.004) for cerebral small vessel disease — consistent with the broader pattern that the A (risk) allele at this locus impairs vascular and neurological aging beyond musculoskeletal function.

The broader 9p21.3 locus literature confirms that ANRIL variants influence CDKN2B expression and cellular senescence⁷⁷ CDKN2B expression and cellular senescence
SNPs here show inverse effects on ANRIL and CDKN2B expression, supporting a role of antisense transcription in regulating senescence pathways, with the risk alleles generally increasing ANRIL expression in ways that paradoxically reduce appropriate p16/p15 upregulation in vascular cells, impairing the normal senescence response to damage. This locus is the strongest genetic signal for coronary artery disease in Europeans (OR ~1.3 per risk allele), though rs2811712 itself does not independently associate with CAD — its primary documented phenotype is functional physical aging.

Practical Actions

For carriers of two A alleles (AA), the evidence supports a targeted approach to slowing the accumulation of senescent cells and their inflammatory secretome. The most directly relevant interventions for the CDKN2B/p16 axis include:

• Senolytic compounds: Fisetin (a flavonoid concentrated in strawberries and onions) and quercetin have demonstrated senolytic activity in human studies — selectively promoting apoptosis in p16-expressing senescent cells. Intermittent high-dose fisetin (≥500 mg/day for 2–3 days per month) reduced senescent cell burden and SASP markers in published clinical data.
• Cardiovascular monitoring: The 9p21.3 region is the strongest common genetic locus for coronary artery disease. While rs2811712 itself does not independently associate with CAD, it tags a haplotype block where other risk variants reside. AA carriers should ensure thorough cardiovascular risk assessment.
• Strength and resistance training: p16-driven muscle senescence contributes directly to sarcopenia (age-related muscle loss) — the leading mediator of physical impairment in older adults. Resistance training specifically reduces senescent cell burden in skeletal muscle and preserves muscle fiber function through mechanisms that parallel the CDKN2B pathway.

AG carriers carry one protective G allele: physical function risk is intermediate, and the same principles apply with moderated urgency.

Interactions

rs10757278 and rs1333049 (9p21.3 haplotype): These are the primary CAD-associated SNPs at the 9p21 locus, in moderate-to-high LD with rs2811712. If you carry the risk haplotype at rs10757278 (G allele) in addition to AA at rs2811712, the combined burden on ANRIL/CDKN2B regulation is likely greater than either marker alone. The 9p21.3 block spans ~58 kb and multiple SNPs contribute to its overall phenotypic effect.

rs564398 (upstream of CDKN2A): Another 9p21 tag SNP associated with type 2 diabetes and glioma risk, which shares the ANRIL regulatory context. Combined risk at rs2811712 and rs564398 may implicate broader ANRIL dysregulation beyond the physical aging phenotype.

Insulin-like growth factor 1 (IGF-1) is one of the most powerful anabolic hormones in the human body. It activates the PI3K/Akt/mTOR pathway¹¹ activates the PI3K/Akt/mTOR pathway
The canonical growth signaling cascade that controls muscle protein synthesis and hypertrophy, stimulates satellite cell activation²² satellite cell activation
Muscle stem cells that divide and fuse to repair damage and create new muscle tissue, and drives skeletal muscle hypertrophy in response to training. The rs35767 polymorphism sits in the promoter region of the IGF1 gene, 1,245 base pairs upstream of the transcription start site, where it regulates how much IGF-1 your body produces.

The A allele is associated with higher circulating IGF-1 levels compared to the C allele, and AA carriers tend to have greater muscle mass and superior athletic performance³³ greater muscle mass and superior athletic performance
Particularly in power and combined power-endurance sports like decathlon. This variant has emerged as one of the most replicated genetic markers for elite athletic performance.

The Mechanism

rs35767 is a regulatory variant located in the promoter region of the IGF1 gene on chromosome 12. The T-to-C substitution at position -1245 affects transcription factor binding and gene expression. Studies show the A allele leads to higher IGF-1 production, though the exact transcription factor interactions remain under investigation. Some research suggests the G allele may allow binding of C/EBPD transcription activator⁴⁴ G allele may allow binding of C/EBPD transcription activator
A DNA-binding protein that regulates gene expression, while other evidence indicates the A allele results in higher circulating levels through mechanisms that may involve altered promoter activity.

Once IGF-1 is secreted (primarily by the liver in response to growth hormone), it binds to IGF-1 receptors on muscle cells. This triggers a signaling cascade: PI3K converts PIP2 to PIP3, activating PDK1 and Akt. Akt then phosphorylates mTORC1, which activates ribosomal protein S6 and translation initiation factor eIF4E, ramping up protein synthesis. Simultaneously, Akt inhibits FoxO transcription factors, blocking the expression of muscle atrophy genes⁵⁵ blocking the expression of muscle atrophy genes
E3 ubiquitin ligases like atrogin-1 and MuRF1 that tag muscle proteins for degradation.

IGF-1 also activates muscle satellite cells—the stem cells responsible for muscle repair and growth. After intense exercise or muscle damage, satellite cells proliferate and differentiate into new myonuclei, contributing approximately half of the muscle mass gained during hypertrophy⁶⁶ half of the muscle mass gained during hypertrophy
Based on studies using viral IGF-1 delivery in animal models.

The Evidence

The rs35767 variant has been studied extensively in athletic populations. In a 2013 Israeli study of 87 power athletes and 78 endurance athletes⁷⁷ 2013 Israeli study of 87 power athletes and 78 endurance athletes
Including international and Olympic-level competitors, the A allele was significantly more frequent in top-level power athletes compared to national-level athletes. Among the elite power cohort, 4.8% carried the TT genotype versus 0% in non-athletic controls—a striking overrepresentation.

A 2022 study of decathlon athletes⁸⁸ 2022 study of decathlon athletes
Decathlon demands both power and endurance across 10 events found the AA genotype was significantly more prevalent among decathletes compared to other athlete groups, and AA carriers demonstrated superior speed performance. These findings align with the physiological role of IGF-1 in fast-twitch muscle fiber development and force production.

A 2024 meta-analysis⁹⁹ 2024 meta-analysis
Pooling data across multiple cohorts to increase statistical power confirmed the A allele as a favorable genetic marker for both power and endurance athletic performance, supporting the variant's role across multiple training modalities.

At the molecular level, a 2014 study of European adults¹⁰¹⁰ 2014 study of European adults
n=569 in discovery cohort measured circulating IGF-1 and found that carriers of the GG genotype (equivalent to TT on the minus strand) had significantly higher IGF-1 levels (218 ng/ml) compared to AA carriers (190 ng/ml, p=0.007). The higher IGF-1 group also showed better insulin sensitivity, suggesting metabolic benefits beyond muscle growth.

However, not all effects are beneficial. A Japanese longitudinal cohort of 1,506 individuals¹¹¹¹ Japanese longitudinal cohort of 1,506 individuals
Followed for long-term health outcomes found that AA carriers experienced faster decline in renal function over time compared to GG carriers, suggesting chronically elevated IGF-1 may have tradeoffs for kidney health.

Practical Actions

If you carry one or two A alleles, you have a genetic advantage for building muscle and responding to strength training. To capitalize on this:

Prioritize resistance training. Your elevated IGF-1 levels mean you're biochemically primed for hypertrophy. Focus on progressive overload—gradually increasing weight, volume, or intensity over time. AA carriers may see faster strength gains and better recovery from high-volume training compared to CC carriers.

Consume adequate protein. IGF-1 activates mTOR, the master regulator of protein synthesis, but mTOR needs amino acid availability to function. Aim for 1.6-2.2 g/kg body weight daily, with post-workout protein intake¹²¹² post-workout protein intake
20-40g within 2 hours of training to maximize the anabolic window when IGF-1 signaling is elevated.

Optimize sleep and recovery. Growth hormone (the primary driver of hepatic IGF-1 production) peaks during deep sleep. AA carriers producing more IGF-1 may benefit even more from adequate sleep (7-9 hours) for muscle repair and satellite cell activation.

Consider monitoring kidney function if you're TT. While the athletic benefits are clear, the Japanese cohort data suggests potential long-term renal effects. If you're a TT carrier pursuing intense athletic training, periodic monitoring of eGFR and creatinine may be prudent, especially as you age or if you have other kidney risk factors.

Interactions

rs35767 interacts with other variants in the IGF axis. rs7136446¹³¹³ rs7136446
An intronic IGF1 variant has also been associated with athletic performance and may compound with rs35767 to influence IGF-1 levels and muscle phenotype. Similarly, rs972936¹⁴¹⁴ rs972936
Another IGF1 intronic variant affects IGF-1 expression and has been linked to neurological outcomes and muscle force production.

Beyond the IGF1 gene, interactions with the growth hormone receptor and myostatin pathway are likely. Carriers of both the IGF1 A allele and myostatin rare R allele¹⁵¹⁵ myostatin rare R allele
Loss-of-function variants in MSTN that reduce this muscle growth inhibitor show even greater muscle mass and performance, suggesting an additive or synergistic effect.

For power athletes, the combination of rs35767 TT and ACTN3 RR¹⁶¹⁶ ACTN3 RR
Alpha-actinin-3, the "gene for speed" may represent an elite genetic profile for explosive strength and sprint performance.

Desmosomes are the mechanical rivets that hold cardiac muscle cells together under the repetitive stress of every heartbeat. Desmoplakin (DSP) is the master scaffold of the desmosome — the only structural protein that spans from the desmosome's cytoplasmic plaque all the way to the intermediate filaments inside the cell. When desmoplakin is compromised, desmosomal integrity fails under mechanical load¹¹ desmosomal integrity fails under mechanical load
DSP is the primary force transducer between the desmosome and the cytoskeleton, triggering a cascade of cellular detachment, fibrosis, and arrhythmia-prone scar tissue. The p.Ser987Pro variant at rs397516929 replaces a serine with proline at position 987 in the protein — a conservative-to-rigid substitution that likely alters the local protein conformation and mechanical resilience of the desmoplakin rod domain.

The Mechanism

The serine-987-to-proline substitution sits within the central rod domain of desmoplakin, a region critical for dimerization and mechanical resistance²² dimerization and mechanical resistance
desmoplakin functions as an antiparallel homodimer linked through its rod domain. Proline is the most conformationally constrained amino acid; its introduction into an alpha-helical region typically breaks or kinks the helix. In the context of a structural protein under cyclical mechanical stress, even partial impairment of rod domain rigidity or dimerization efficiency could reduce the desmosome's ability to maintain intercellular adhesion during high-demand periods.

Heterozygous loss-of-function in DSP causes disease through haploinsufficiency — one damaged copy reduces total desmoplakin output below the threshold required for sustained mechanical integrity in cardiomyocytes. The result is cardiomyocyte detachment, fatty-fibrous replacement, and patchy subepicardial fibrosis³³ cardiomyocyte detachment, fatty-fibrous replacement, and patchy subepicardial fibrosis
the fibrosis precedes and is disproportionate to systolic dysfunction in DSP cardiomyopathy, creating an arrhythmia-prone substrate that can trigger ventricular tachycardia and sudden cardiac death — often while left ventricular ejection fraction (LVEF) is still preserved.

DSP cardiomyopathy has a distinct inflammatory dimension absent from most heritable cardiomyopathies: 14–22% of carriers experience acute "hot phase" episodes of chest pain, troponin elevation, and new late gadolinium enhancement⁴⁴ 14–22% of carriers experience acute "hot phase" episodes of chest pain, troponin elevation, and new late gadolinium enhancement
mimicking myocarditis or acute coronary syndrome but without obstructive coronary disease. These episodes accelerate fibrosis accumulation and substantially increase subsequent arrhythmia risk.

The Evidence

DSP cardiomyopathy has been characterized in detail only in the past six years, and the Ser987Pro specific variant (ClinVar VCV000044888) has a single ClinVar submission from Mass General Brigham (2009, no assertion criteria), based on two patients with arrhythmogenic right ventricular cardiomyopathy. The variant is essentially absent from gnomAD population databases — consistent with a high-penetrance pathogenic variant under strong negative selection.

The broader DSP cardiomyopathy literature, however, is now substantial. Smith et al. (Circulation 2020) studied 107 patients with pathogenic DSP variants⁵⁵ Smith et al. (Circulation 2020) studied 107 patients with pathogenic DSP variants
Desmoplakin cardiomyopathy is a fibrotic and inflammatory form distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathy. Circulation 141:1872–1884, 2020 and showed that left ventricular predominant disease occurred in 55% of DSP patients (versus 0% for PKP2 mutations), with subepicardial late gadolinium enhancement in 40% and normal LVEF preserved in 35% of imaging-positive patients — fibrosis preceding dysfunction.

Wang et al. (Europace 2022), following 91 DSP variant carriers for a median 4.3 years⁶⁶ Wang et al. (Europace 2022), following 91 DSP variant carriers for a median 4.3 years
Clinical characteristics and risk stratification of desmoplakin cardiomyopathy. Europace 24:268–277, 2022, found a sustained ventricular arrhythmia (VA) incidence of 5.9 per 100 person-years. Myocardial injury events — the "hot phase" episodes — strongly predicted both arrhythmia (HR not quantified in abstract) and heart failure (HR not quantified).

The largest cohort to date, Gasperetti et al. (Eur Heart J 2025), enrolled 800 patients from 26 institutions⁷⁷ Gasperetti et al. (Eur Heart J 2025), enrolled 800 patients from 26 institutions
Clinical features and outcomes in carriers of pathogenic desmoplakin variants. Eur Heart J 46:362–376, 2025. Over 3.7-year follow-up, 17.4% developed sustained VA (3.9%/year) and 9.0% required heart failure hospitalization (1.8%/year). Independent VA predictors included female sex (aHR 1.547), prior non-sustained VT (aHR 1.721), prior sustained VA (aHR 1.923), LVEF ≤50% (aHR 1.645), and myocardial injury episodes (HR 2.394). Critically, 32.5% of patients met no conventional diagnostic criteria for ARVC, DCM, or NDLVC — underscoring that standard phenotypic thresholds miss many DSP carriers.

Bariani et al. (Heart Rhythm 2022), 73 Italian DSP carriers⁸⁸ Bariani et al. (Heart Rhythm 2022), 73 Italian DSP carriers
Clinical profile and long-term follow-up of a cohort of patients with desmoplakin cardiomyopathy. Heart Rhythm 2022, found major ventricular arrhythmias in 29% overall, with males experiencing dramatically worse outcomes: 52% arrhythmia vs 24% in females (p=0.036), and 31% cardiac death in males vs 0% in females (p<0.001). Females showed preferential left ventricular involvement.

The DSP Risk Score (Carrick et al., Eur Heart J 2024)⁹⁹ DSP Risk Score (Carrick et al., Eur Heart J 2024)
A novel tool for arrhythmic risk stratification in desmoplakin gene variant carriers. Eur Heart J 45:2968, 2024 integrates five clinical parameters — female sex, non-sustained VT history, PVC burden, LVEF <50%, and moderate-to-severe RV dysfunction (HR 6.0) — into a validated risk model with c-statistic 0.782, stratifying patients into low (<5%), intermediate (5–20%), and high-risk (>20%) five-year arrhythmia categories.

Practical Actions

DSP cardiomyopathy is actionable precisely because it is heritable (autosomal dominant, each child of a carrier has 50% risk), penetrant but variable in timing, and progressive in proportion to cumulative fibrosis. Carriers who are identified before symptoms emerge have the greatest window for preventive monitoring.

Cardiac magnetic resonance imaging (CMR) is the cornerstone of evaluation — echocardiography misses subepicardial fibrosis detectable only as late gadolinium enhancement. Ambulatory ECG monitoring quantifies PVC burden, one of the five parameters in the validated DSP risk score. Competitive sports restriction is recommended for carriers with confirmed disease phenotype, as exercise-induced myocardial stress can trigger "hot phase" episodes and accelerate fibrosis. For those progressing to high VA burden or reduced LVEF, ICD consideration follows standard ESC/AHA heart failure guidelines — though the LVEF <35% threshold used in dilated cardiomyopathy is insensitive for DSP disease, where arrhythmia risk is elevated even with preserved ejection fraction.

First-degree relatives of confirmed carriers should undergo clinical and genetic evaluation. Cascade genetic testing identifies pre-symptomatic carriers before fibrosis has accumulated.

Interactions

DSP cardiomyopathy shares phenotypic overlap with PKP2 (plakophilin-2) and DSG2 (desmoglein-2) variants — all desmosomal genes whose proteins form the macromolecular complex at the intercalated disc. Compound heterozygosity or digenic combinations with PKP2 variants have been reported and may produce more severe phenotypes with earlier onset and biventricular involvement, though systematic data on specific genotype combinations are limited. SCN5A variants (sodium channel) have been found as potential modifiers of arrhythmia severity in some desmosomal cardiomyopathy families. Carriers with concurrent hypertension or obesity face accelerated fibrosis progression due to increased hemodynamic wall stress amplifying desmosomal vulnerability.

Your brain makes its own cholesterol — and unlike the rest of your body, it has almost no way to get rid of it. The blood-brain barrier blocks cholesterol from simply diffusing out, so the brain relies almost entirely on a single enzyme, cholesterol 24-hydroxylase¹¹ cholesterol 24-hydroxylase
encoded by CYP46A1, a cytochrome P450 enzyme expressed almost exclusively in neurons, to convert excess cholesterol into 24S-hydroxycholesterol (24S-OHC) — a metabolite that can cross the blood-brain barrier and exit the brain. This makes CYP46A1 the primary gatekeeper of brain cholesterol homeostasis and a direct regulator of how much cholesterol accumulates in neurons over time.

The Mechanism

rs4900442 sits in intron 3 of the CYP46A1 gene (the IVS3+43 C>T variant), placing it in a non-coding region that likely influences mRNA splicing efficiency or regulatory element binding rather than the amino acid sequence of the enzyme itself. The C allele, which is the reference allele and the globally more common variant (~55% frequency), appears to be associated with altered enzyme activity or expression — manifesting as a higher ratio of 24S-hydroxycholesterol to cholesterol in cerebrospinal fluid²² 24S-hydroxycholesterol to cholesterol in cerebrospinal fluid
CSF levels of 24S-OHC reflect the rate of CYP46A1-catalysed cholesterol turnover in the brain; an elevated ratio suggests dysregulated flux among CC homozygotes with Alzheimer's disease. Disrupted brain cholesterol turnover is mechanistically plausible as an Alzheimer's risk pathway: cholesterol accumulation in neuronal membranes can promote amyloid-beta production and tau phosphorylation, both core features of AD pathology.

The Evidence

The original association was reported by Kölsch et al. in 2002³³ Kölsch et al. in 2002
Kölsch H et al. Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer's disease. Mol Psychiatry 2002;7:899–902 in a German cohort of 114 AD patients and 144 healthy controls. They found the C allele of the IVS3+43 C>T variant significantly more prevalent in AD patients, and additionally demonstrated that CC genotype carriers had an elevated 24S-OHC/cholesterol ratio in CSF — providing a direct biochemical link between genotype and brain cholesterol metabolism.

A 2016 meta-analysis by Jia et al.⁴⁴ 2016 meta-analysis by Jia et al.
Jia F et al. The association between CYP46A1 rs4900442 polymorphism and the risk of Alzheimer's disease: a meta-analysis. Neurosci Lett 2016;620:83–87 pooled six case-control studies covering 1,555 AD cases and 1,347 controls. The overall analysis found no statistically significant association (allele model OR=0.947), but a significant protective effect of the T allele emerged specifically in Chinese populations (OR=0.780, 95% CI 0.628–0.968), with no equivalent signal in Caucasian cohorts. This population-specific finding is consistent with the broader literature on CYP46A1 variants, where effect sizes and directions vary substantially across ancestries.

A related but distinct variant (rs754203, the intron 2 T/C polymorphism) has been more extensively studied and shows similarly mixed results in the largest meta-analysis to date — 21 studies, 4,875 AD cases, 4,874 controls — where the CC genotype of that neighboring variant confers modestly increased risk (recessive model OR=1.20) and the effect is amplified among APOE ε4 carriers⁵⁵ amplified among APOE ε4 carriers
Li L et al. CYP46A1 T/C polymorphism associated with the APOE ε4 allele increases the risk of AD. J Neurol 2013;260:1446–1455. The rs4900442 and rs754203 variants are in partial linkage disequilibrium and likely tag overlapping haplotypes within the CYP46A1 locus.

The overall evidence picture is moderate: the biological mechanism is well-established (CYP46A1 controls the dominant route of brain cholesterol elimination), the CSF biomarker data provide functional support, but the genetic association is population-specific and the effect size is modest.

Practical Actions

The actionable implication of impaired CYP46A1 function focuses on modifiable factors that can influence brain cholesterol homeostasis through parallel routes. The most important consideration is the well-documented interaction with APOE genotype: the risk associated with CYP46A1 C alleles appears substantially amplified in APOE ε4 carriers, making combined genotyping particularly informative.

Efavirenz⁶⁶ Efavirenz
an antiretroviral drug that acts as a low-dose CYP46A1 activator — repurposing studies are underway has been investigated at sub-therapeutic doses as a pharmacological activator of CYP46A1, and early research suggests it may restore normal brain cholesterol turnover. This is a research-stage observation and not a current clinical recommendation.

Statins do not readily cross the blood-brain barrier and do not directly substitute for CYP46A1 function in the brain; they act on peripheral cholesterol, leaving brain cholesterol metabolism largely untouched.

Interactions

The most clinically relevant interaction is with rs429358 (APOE ε4 determinant). Li et al. 2013 demonstrated that APOE ε4 carriers with the CC genotype at the related rs754203 locus (and by extension, likely at rs4900442) face significantly greater Alzheimer's disease risk than either risk factor alone would predict. CYP46A1 and APOE are both central to brain lipid metabolism, and their interaction is mechanistically coherent: impaired 24S-OHC production compounds with APOE ε4-driven amyloid accumulation.

The intron 2 variant rs754203 is the most extensively studied CYP46A1 polymorphism in Alzheimer's disease research. rs4900442 and rs754203 are in partial LD and likely tag the same underlying haplotype structure within the CYP46A1 locus. Their combined effect has not been formally modeled in published studies.

Toll-like receptor 4 (TLR4)¹¹ Toll-like receptor 4 (TLR4)
The primary innate immune receptor for lipopolysaccharide (LPS), a structural component of Gram-negative bacterial cell walls orchestrates your body's first response to bacterial threats. The Thr399Ile variant (rs4986791) — a C-to-T transition at coding position 1196 that replaces threonine with isoleucine at protein position 399²² replaces threonine with isoleucine at protein position 399
This occurs in the extracellular domain of TLR4 — is an important functional variant in its own right, yet one that has long lived in the shadow of its neighbor.

Unlike the Asp299Gly variant (rs4986790), Thr399Ile does not independently disrupt TLR4 signaling in isolated cell-culture experiments. But in living humans, these two variants almost always travel together on the same chromosome. They co-segregate on a single haplotype³³ They co-segregate on a single haplotype
Most carriers of Thr399Ile are also carriers of Asp299Gly, and vice versa. This tight genetic coupling means their combined effect on immune recognition — reduced LPS sensing, dampened cytokine production, altered neutrophil responses — is the relevant biology for nearly everyone carrying either variant. The T allele occurs at about 6.4% frequency in Europeans but is exceptionally rare in East Asians (0.04%); interestingly, South Asians and Finns show notably higher frequencies (~10.5% and ~12.2% respectively).

GWAS analyses provide an independent line of evidence: rs4986791 is among the strongest genetic determinants of TLR4:MD-2 protein complex levels in blood (MD-2 is the co-receptor that enables TLR4 to recognize LPS), with effect sizes reaching beta = −0.94 to −1.27 at p < 10⁻³⁴, indicating the T allele substantially reduces circulating TLR4/MD-2 complex abundance regardless of the co-occurring Asp299Gly variant.

The Mechanism

Thr399Ile sits in the extracellular domain of TLR4, in a region involved in forming the receptor complex with MD-2 and LPS. While functional studies using isolated Thr399Ile-only constructs found no independent disruption of LPS-induced NF-κB signaling, the variant reduces TLR4:MD-2 protein complex abundance at the cell surface. When combined with Asp299Gly on the same haplotype, neutrophils show reduced phosphorylation of IκB⁴⁴ reduced phosphorylation of IκB
IκB is the inhibitor of NF-κB; its reduced phosphorylation means NF-κB stays in its inactive state, blunting inflammatory gene transcription, diminished IL-6 and TNF-α production after LPS stimulation, and reduced suppression of apoptosis — the combination yielding a pronounced loss-of-function phenotype in real-world immune contexts.

The Evidence

The inflammatory bowel disease evidence is among the most replicated findings. A meta-analysis of 49 case-control studies found significant associations between rs4986791 and IBD risk⁵⁵ A meta-analysis of 49 case-control studies found significant associations between rs4986791 and IBD risk
Analysis included both Crohn's disease and ulcerative colitis. A separate meta-analysis confirmed significantly higher frequencies of Thr399Ile in patients with IBD, Crohn's disease, and ulcerative colitis⁶⁶ A separate meta-analysis confirmed significantly higher frequencies of Thr399Ile in patients with IBD, Crohn's disease, and ulcerative colitis
The 399Ile allele carriage was elevated in UC patients as well as CD patients in this analysis. These findings are biologically coherent: reduced TLR4 recognition of gut-resident bacteria is thought to impair mucosal immune homeostasis, allowing commensals to trigger aberrant inflammation.

For sepsis, the picture is clearer than for Asp299Gly. A meta-analysis of 17 studies encompassing 2,212 cases and 3,880 controls found an odds ratio of 1.16 (95% CI: 0.70–1.91, p = 0.57) for Thr399Ile and sepsis⁷⁷ A meta-analysis of 17 studies encompassing 2,212 cases and 3,880 controls found an odds ratio of 1.16 (95% CI: 0.70–1.91, p = 0.57) for Thr399Ile and sepsis
This non-significant result held across Caucasian populations. There is no meaningful independent association between this variant and sepsis susceptibility.

Emerging evidence links rs4986791 to cancer susceptibility. A meta-analysis of 87 case-control studies found the T allele associated with increased cancer risk (OR 0.74 for C vs T model)⁸⁸ A meta-analysis of 87 case-control studies found the T allele associated with increased cancer risk (OR 0.74 for C vs T model)
The study spanned prostate, lung, gastric, hepatocellular, and colorectal cancers, among others. A separate case-control study found rs4986791 variant genotypes associated with increased acute myeloid leukemia (AML) susceptibility, OR 1.61 (95% CI: 1.001–2.59) in the dominant model⁹⁹ rs4986791 variant genotypes associated with increased acute myeloid leukemia (AML) susceptibility, OR 1.61 (95% CI: 1.001–2.59) in the dominant model
The combined effect of rs4986790 + rs4986791 yielded OR 3.14 for AML development. For respiratory disease, a meta-analysis of 11 studies found significant asthma association especially among Asian populations¹⁰¹⁰ a meta-analysis of 11 studies found significant asthma association especially among Asian populations
One pediatric study found CT genotype children were more likely to develop severely persistent asthma.

Practical Implications

Because Thr399Ile almost always co-occurs with Asp299Gly, the practical actions for carriers mirror those for Asp299Gly carriers — vigilant infection prevention, attention to gastrointestinal symptoms, and awareness of IBD risk. The additional evidence here for asthma and cancer susceptibility adds nuance: the T allele appears to be a general marker of altered innate pattern recognition, with downstream consequences across multiple inflammatory and immune-surveillance pathways.

The significantly reduced TLR4:MD-2 complex levels in T allele carriers suggest a mechanistically grounded reason for the reduced immune surveillance: there are simply fewer functional receptor complexes available to detect bacterial signals at mucosal surfaces.

Interactions

Thr399Ile (rs4986791) and Asp299Gly (rs4986790) co-segregate on the same haplotype in virtually all carriers¹¹¹¹ co-segregate on the same haplotype in virtually all carriers
In population studies, essentially every Thr399Ile carrier also carries Asp299Gly. This means interpreting either variant in isolation is biologically incomplete. The compound haplotype shows more pronounced impairment of innate immune responses than either variant alone, including reduced neutrophil NF-κB activation and cytokine production. This interaction is the most important genetic context for rs4986791 — for most carriers, the functional picture is the same as for the compound double carrier. TLR4 co-receptor variants such as the CD14 -260 C>T polymorphism, which alters CD14 expression and LPS delivery to TLR4, may further modulate the effect of this haplotype on mucosal immunity and IBD risk.

Most people have heard of Factor V Leiden or prothrombin G20210A as genetic drivers of venous blood clots. TC2N (Tandem C2 Domains, Nuclear) barely appeared on coagulation researchers' radar until 2022 — yet genome-wide studies now place this gene at a locus with one of the most statistically significant associations with venous thromboembolism (VTE) identified to date. VTE¹¹ VTE
venous thromboembolism, encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE) is responsible for approximately 100,000–300,000 deaths per year in the United States alone. Understanding its genetic architecture helps identify people at elevated baseline risk who may benefit from more vigilant prevention strategies.

The Mechanism

TC2N encodes a 490-amino-acid protein containing two tandem C2 domains²² C2 domains
calcium- and lipid-binding structural motifs found in many signaling proteins, including synaptotagmins and protein kinase C (C2A spanning residues 223–342; C2B spanning residues 344–471). The protein carries a nuclear localization signal and is predicted to be active in the nucleus, with phosphorylation sites documented in platelet proteomics datasets — raising the possibility that TC2N participates in nuclear signaling cascades relevant to hemostatic cell function.

The rs57035593 variant sits deep within intron 5 of TC2N (c.469+502, 502 nucleotides from the exon boundary) on the minus strand of chromosome 14q32.12. As an intronic variant, it does not change the TC2N protein sequence. Instead, it almost certainly acts as a tag SNP³³ tag SNP
a variant in strong linkage disequilibrium with a nearby causal regulatory or coding variant that is harder to genotype directly or as a regulatory element affecting TC2N expression in relevant tissues. GTEx data show that this variant is an eQTL for the nearby CATSPERB gene in whole blood, suggesting complex local regulatory architecture in this chromosomal region.

The biological plausibility of TC2N in hemostasis was formally tested and confirmed: CRISPR/Cas9 knockdown of tc2n in zebrafish⁴⁴ CRISPR/Cas9 knockdown of tc2n in zebrafish
laser-mediated endothelial injury model; fish with tc2n knockdown showed significantly abnormal thrombus formation, demonstrating the gene is required for normal in vivo hemostasis produced a measurable hemostatic phenotype in the laser endothelial injury model, placing TC2N alongside well-validated coagulation genes. This makes TC2N one of only a handful of GWAS-nominated VTE loci to have direct experimental functional validation in an in vivo model.

The Evidence

The primary GWAS evidence comes from a landmark cross-ancestry meta-analysis by Thibord et al.⁵⁵ cross-ancestry meta-analysis by Thibord et al.
Circulation 2022, 81,669 VTE cases and controls across European, African, and Hispanic ancestries, 135 independent loci, GCST90797304 which identified rs57035593 at genome-wide significance (p = 3×10⁻³⁸, β = 0.071 per T allele). This effect size, while modest on an individual scale, is consistent with the polygenic architecture of VTE — cumulative risk from many loci adds up substantially.

Independent confirmation comes from Ghouse et al.⁶⁶ Ghouse et al.
Nature Genetics 2023, 81,190 VTE cases and 1,419,671 controls, 93 risk loci of which 62 were previously unreported and the subsequent Wolford et al. multipopulation GWAS⁷⁷ Wolford et al. multipopulation GWAS
Blood Advances 2025, 27,987 cases and 1,035,290 controls from 9 international cohorts, 38 genome-wide significant loci, which provided the zebrafish validation. Together these three large studies, spanning over 100,000 VTE cases globally, converge on TC2N as a genuine VTE susceptibility locus with both statistical and experimental support.

Practical Actions

TC2N rs57035593 is a common variant — roughly half of people globally carry at least one T allele. Like other polygenic VTE risk factors, it operates in the background of overall thrombotic risk, amplified by situational risk factors such as prolonged immobility, surgery, oral contraceptive use, pregnancy, cancer, or dehydration. People who carry two T alleles (about 8–11% of Europeans and East Asians) carry the highest baseline genetic risk from this particular locus.

Because anticoagulant therapy for primary VTE prevention has its own bleeding risks, genetic risk alone is not sufficient to justify prophylactic anticoagulation. The clinical value of knowing this genotype lies in heightened awareness during high-risk periods: long-haul travel, hospitalization, post-surgical recovery, and pregnancy. These are the windows where preventive measures — compression stockings, early mobilization, adequate hydration, and when clinically indicated, pharmacological prophylaxis — have strong evidence behind them.

Interactions

TC2N rs57035593 is one of over 90 validated VTE susceptibility loci. Its effect is additive with other known thrombophilic variants: Factor II prothrombin G20210A (rs1799963), Factor V Leiden (rs6025), and fibrinogen gamma-chain variants (rs2066865). Individuals who carry rs57035593-TT alongside any of these high-penetrance variants face compounded risk that approaches the level seen with monogenic thrombophilias. The Ghouse et al. polygenic risk score showed that individuals in the top 0.1% of cumulative genetic VTE risk have risk equivalent to homozygous F2/F5 variant carriers — a finding that underscores why the full polygenic context matters.

Oral contraceptives and hormone replacement therapy are the most clinically relevant environmental interactions: estrogen-containing preparations increase VTE risk 3–6-fold in the general population, and this effect is additive with genetic predisposition from multiple VTE loci including TC2N.